Nifedipine on coronary vsacular function after drug eluting stent implantation

Nifedipine on coronary vsacular function after drug eluting stent implantation - NOVEL study (Nifedipine On coronary Vsacular function after drug ELuting stent implantation)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015147

Enrollment

100

Registered

2014-09-16

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

Control: Conventional medication (aspirin, clopidogrel, atorvastatin, standard dose of renin-angiontensin system inhibitor) Interventions: Adding the long-acting nifedipine (adalat CR) to conventional

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stable angina pectoris patient planned to everolimus-eluting stent within 3 months

Exclusion criteria

Exclusion criteria: Acute coronary syndrome, History of stent implantation in left coronary artery, Vasospastic angina, History of in-stent restenosis, Heart failure with reduced LVEF (<40%), Severe liver dysfunction, Intolerability to dihydropyridin calcium channel blocker, Inappropriate patient considered by an attending doctor

Design outcomes

Primary

Measure	Time frame
The vasoconstricting response to Acetylcholine 8-10 months after stent implantation (Quantitative coronary angiolgraphy)	—

Secondary

Measure	Time frame
Blood pressure, heart rate, recurrence of angina pectoris, frequency of angina symptom, biomarker (hs-CRP, adiponectin, PTX3), in-stent restenosis, severe adverse event	—

Countries

Japan

Contacts

Public ContactJun Takahashi

Tohoku University Graduate School of Medicne Department of Cardiovascular Medicine

jtakahashi@cardio.med.tohoku.ac.jp022-717-7153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026